.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Citi
Baxter
Merck
US Army
Healthtrust
Boehringer Ingelheim
Queensland Health
Fish and Richardson
AstraZeneca
Accenture

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,011,848

« Back to Dashboard

Summary for Patent: 7,011,848

Title:Hydrophobic component free sustained release nicotinic acid compositions for treating hyperlipidemia and related methods therefor
Abstract:An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day "nocturnally," that is in the evening or at night.
Inventor(s): Bova; David J. (Hollywood, FL)
Assignee: KOS Pharmaceuticals, Inc. (Miami, FL)
Application Number:09/470,603
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Formulation;

No matches for this query

International Patent Family for Patent: 7,011,848

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway994275► Subscribe
Norway994248► Subscribe
Finland19991896► Subscribe
Finland119910► Subscribe
Finland19991895► Subscribe
Spain2234100► Subscribe
European Patent Office2319513► Subscribe
European Patent Office0969837► Subscribe
European Patent Office0966284► Subscribe
European Patent Office0643965► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Teva
McKesson
Deloitte
Healthtrust
US Army
QuintilesIMS
Novartis
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot